Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Enhertu’s Tumor-Agnostic Use Now under EU Review: Daiichi Sankyo
Daiichi Sankyo said on September 11 that EU regulators have accepted for review its antibody drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) for the treatment of unresectable or metastatic HER2 positive solid cancers. If approved, Enhertu would become the first HER2…
To read the full story
Related Article
- Enhertu Snags EU Approval in HER2 Positive Solid Tumors
June 30, 2026
- Enhertu Earns EMA Panel OK for HER2 Positive Solid Tumors
May 25, 2026
- Enhertu Nabs Pan-Tumor Indication in US: Daiichi Sankyo
April 9, 2024
BUSINESS
- Kineret Could Bring Earlier Remission in Still’s Disease: Expert
September 8, 2026
- Shionogi’s Cefiderocol Approved in Australia
September 8, 2026
- Argenx Recalls 1 Lot of Vyvdura as Precaution over Foreign Matter
September 8, 2026
- Japan Ethical Drug Sales Rise 4.8% in July: Crecon
September 8, 2026
- Keytruda Holds Top Spot for 35th Straight Month in August: Encise
September 7, 2026
Japanese Prime Minister Sanae Takaichi has pledged to respond to the US most-favored-nation (MFN) drug pricing policy to safeguard timely…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…